Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Growth Projections For The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Size During 2025–2029?
The bioinformatics in in-vitro diagnostics (ivd) testing market has demonstrated robust expansion over recent years. Its valuation is expected to ascend from $93.02 billion in 2024 to $98.89 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.3%. This historical growth can be ascribed to factors such as better healthcare infrastructure, the proliferation of biobanks, an increasing elderly demographic, various government initiatives and funding mechanisms, and the advancement of personalized medicine.
The market for bioinformatics in in-vitro diagnostics (IVD) testing is projected to experience robust expansion over the coming years. This market is forecast to reach $126.76 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.4%. Several factors contribute to this projected increase, including an escalating incidence of diseases, the incorporation of IT within healthcare, governmental support and investment, a move towards tailored medical approaches, greater understanding of bioinformatics advantages in diagnostics among medical professionals, and a reduction in genomic sequencing expenses. Key developments anticipated during this timeframe encompass artificial intelligence (AI) and machine learning, next-generation sequencing, point-of-care (POC) testing, cloud computing and big data, alongside advancements in immunochemical methodologies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16629&type=smp
What Are The Drivers Pushing New Developments In The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?
The escalating incidence of cancer is anticipated to drive the expansion of the bioinformatics in IVD testing market in the future. Cancer is a broad categorization for diseases characterized by uncontrolled cell growth, which can invade and spread to other parts of the body. The increasing frequency of cancer can be attributed to various factors such as exposure, lifestyle, and environmental influences. Bioinformatics in IVD testing revolutionizes cancer diagnostics by delivering precise, personalized, and comprehensive genetic data, thereby enhancing early detection, informing treatment decisions, and improving patient outcomes. For instance, in 2022, the National Association of Chronic Disease Directors (NACDD), a U.S.-based government agency, reported that approximately 40% of American adults live with multiple chronic conditions (MCC), and there is increasing evidence that possessing one chronic illness raises the risk of acquiring additional ones, especially with advancing age. Therefore, the rising prevalence of cancer fuels the bioinformatics in the IVD testing market.
What Are The Emerging Segments Gaining Attention In The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?
The bioinformatics in in-vitro diagnostics (ivd) testingmarket covered in this report is segmented –
1) By Type: Hardware; Software
2) By Type Of Test: Blood Based Tests; Tissue Based Tests
3) By Application: Cardiovascular Diseases; Chronic Diseases; Diabetes; Cancer; Other Applications
Subsegments:
1) By Hardware: Analyzers; Laboratory Equipment; Data Storage Devices; Sensors And Detectors; Workstations And Data Processing Hardware
2) By Software: Bioinformatics Platforms; Data Management and Integration Software; Analytics And Interpretation Software; Cloud-Based Software Solutions; AI-Based Software For Diagnostics
What Trends Are Expected To Drive The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?
Leading companies active in the bioinformatics in the IVD testing market are focusing on creating advanced solutions, such as next-generation sequencing (NGS) technology, to boost the detection and analysis of genetic mutations, refine diagnostic accuracy, and support personalized medicine strategies. Next-generation sequencing (NGS) represents a high-throughput method facilitating the rapid sequencing of entire genomes or specific DNA and RNA regions, thereby enabling comprehensive genetic analysis. For instance, in May 2022, Illumina Inc., a US-based biotechnology company, unveiled a new pan-cancer companion diagnostic (CDx) indication for its CE-marked TruSight Oncology Comprehensive (EU) test. This advancement enables the test to identify cancer patients with solid tumors who possess neurotrophic tyrosine receptor kinase (NTRK) gene fusions, specifically NTRK1, NTRK2, or NTRK3, and who might benefit from targeted therapy with Bayer’s drug Vitrakvi (larotrectinib). The TSO Comprehensive (EU) test functions as a comprehensive genomic profiling (CGP) assay, incorporating next-generation sequencing to analyze numerous tumor genes and biomarkers from a single biopsy specimen to ascertain a patient’s distinct cancer molecular profile.
Who Are The Prominent Global Companies Shaping The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?
Major companies operating in the bioinformatics in in-vitro diagnostics (IVD) testing market are Siemens Healthineers, International Business Machines Corporation, Medtronic Inc., Parker Hannifin Corp., Illumina Inc, PerkinElmer Inc., QIAGEN N.V., Kollmorgen Corp, Bioreference Laboratories Inc., AssureRx Health Inc., Biodesix Inc., Crescendo Bioscience Inc., Affymetrix, Complete Genomics Inc., Aperico Technologies Inc., One Lambda Inc., Datech Oncology, Life Technologies, Signal genetics, CardioDx Inc.
Download The Full Report For Exclusive Market Findings:
Which Global Regions Are Influencing The Competitive Landscape Of The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?
North America was the largest region in the bioinformatics in in-vitro diagnostics (IVD) testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioinformatics in in-vitro diagnostics (IVD) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Report:
https://www.thebusinessresearchcompany.com/customise?id=16629&type=smp
Browse Through More Reports Similar to the Global Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market 2025, By The Business Research Company
In Vitro Diagnostics Ivd Quality Control Global Market Report 2025
In Vitro Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report
Bioinformatics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/bioinformatics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model